Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aldeyra Therapeutics, Inc (ALDX) Fair Value & Analysis

Healthcare · US · Market cap $110M

Price$2.02
Fair Value$3.30
Upside+63.4%
Quality95/100
Evidence: Low Range $2.48 – $4.13

Fair value as of: Jun 24, 2026

Analysis

Aldeyra Therapeutics, Inc (ALDX) currently trades at $2.02, while our model-based Fair Value estimate is $3.30 — implying the stock looks roughly 63.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Aldeyra Therapeutics, Inc (ALDX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.30 versus a price of $2.02 — about +63% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ALDX?
Our 21-model fair value for Aldeyra Therapeutics, Inc is $3.30 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.02.
What is the quality score of ALDX?
Aldeyra Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.